Project profile — Advance Market Commitment for Pneumococcal Vaccines (I)

• Africa, regional (25.00%)
• America, regional (25.00%)
• Asia, regional (25.00%)
• Europe, regional (25.00%)

• Basic Health: Infectious disease control (12250) (100.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (principal objective)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)

The Advance Market Commitment (AMC) is a financial commitment by multiple donors to help pay for the future purchase of a vaccine for pneumococcal disease, a leading cause of child deaths from pneumonia and meningitis in developing countries. Pneumococcal disease is responsible for more than 1.7 million deaths per year. Of these deaths almost 90% occur in developing countries, and half occur among children under age five. The AMC is an innovative way to protect the lives of the world’s poorest children by making vaccines available in developing countries more quickly. It is based on the concept of putting money aside to guarantee the purchase of vaccines once they are developed as long as they meet criteria specifically set out for the developing world. It aims to stimulate vaccine makers to accelerate the development of vaccines and sell them at prices that poor countries can afford. The total donor commitment to the AMC is US$1.5 billion. These funds allow for the implementation of the AMC concept by the World Bank and the GAVI Alliance. Canada’s commitment to the AMC is US$200 million. This project represents an initial contribution of C$115 million. The AMC is expected to save an estimated 7 million lives by 2030.

N/A

Results achieved at the end of the project (2011) Include: GAVI helped 16 developing countries to introduce the new anti pneumococcal vaccine nationally for the first time.

• Proactive disclosure
• Related activities: Advance Market Commitment for Pneumococcal Vaccines (II)